OliX Pharmaceuticals, Inc (KOSDAQ:226950)
South Korea · Delayed Price · Currency is KRW 186,900
+5,100 (2.81%)
At close: Mar 20, 2026
OliX Pharmaceuticals Revenue
In the year 2025, OliX Pharmaceuticals had annual revenue of 14.67B KRW with 158.35% growth. OliX Pharmaceuticals had revenue of 4.53B in the quarter ending December 31, 2025, with 9,920.28% growth.
Revenue
14.67B
Revenue Growth
+158.35%
P/S Ratio
257.28
Revenue / Employee
n/a
Employees
n/a
Market Cap
3.77T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 14.67B | 8.99B | 158.35% |
| Dec 31, 2024 | 5.68B | -11.39B | -66.73% |
| Dec 31, 2023 | 17.06B | 7.74B | 83.09% |
| Dec 31, 2022 | 9.32B | 5.65B | 153.66% |
| Dec 31, 2021 | 3.67B | 1.20B | 48.50% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Chabiotech | 1.20T |
| SK Biopharmaceuticals | 706.74B |
| SK bioscience | 651.37B |
| PharmaResearch | 496.03B |
| Hugel | 425.10B |
| LigaChem Biosciences | 159.27B |
| HLB Co., Ltd. | 80.73B |
| D&D Pharmatech | 8.36B |